Nucleai to Publish Pathology-based Data at ASCO 2022 for Phase 2 Research of the Most Common Type of Non-Hodgkin’s Lymphoma
CHICAGO--(BUSINESS WIRE)--#AIpowered--Nucleai, an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking...
